Gallop Oncology will present new data from its ongoing Phase 1b clinical trial of LYT-200 for relapsed/refractory acute myeloid leukemia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE